M. E. Pavel, J. D. Hainsworth, E. Baudin, M. Peeters, D. Horsch, R. E. Winkler, et al., “Everolimus Plus Octreotide Long-Acting Repeatable for the Treatment of Advanced Neuroendocrine Tumours Associated with Carcinoid Syndrome (RADIANT 2): A Randomised, PlaceboControlled, Phase 3 Study,” The Lancet, Vol. 378, No. 9808, 2011, pp. 2005-2012. doi:10.1016/S0140-6736(11)61742-X

has been cited by the following article:

• TITLE: Prolonged Radiographic Stabilization of a Metastatic Octreotide Scan-Positive Poorly Differentiated Neuroendocrine Tumor Using Octreotide Acetate Therapy Alone

  AUTHORS: Steven Sorscher

  KEYWORDS: PDNET; Octreotide Acetate; Pancreatic Cancer; mTOR Overexpression

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.7, August 16, 2013

  ABSTRACT: Pancreatic poorly differentiated neuroendocrine tumors (PDNETs) are a subtype of neuroendocrine Tumors (NETs) clinically distinguished by their much more rapid growth and immunohistochemically diagnosed by having a higher Ki-67 cancer cell staining percentage compared to their well or intermediately differentiated NET counterparts. While standard first line treatment for metastatic well or intermediately differentiated pancreatic NETs typically involves octreotide acetate therapy, here I report, to my knowledge, the first case of a patient with a pancreatic PDNET with radiographic stabilization of his disease with octreotide acetate use alone. Octreotide acetate was chosen after first establishing that, based on his octreotide scan, receptors might be targeted using the octreotide analog.